These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23152093)

  • 1. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study.
    Kang JH; Keller JJ; Lin HC
    Osteoporos Int; 2013 Jan; 24(1):271-7. PubMed ID: 23152093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke.
    Kang JH; Keller JJ; Lin HC
    Osteoporos Int; 2012 Oct; 23(10):2551-7. PubMed ID: 22270858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial infarction risk among patients with fractures receiving bisphosphonates.
    Pittman CB; Davis LA; Zeringue AL; Caplan L; Wehmeier KR; Scherrer JF; Xian H; Cunningham FE; McDonald JR; Arnold A; Eisen SA
    Mayo Clin Proc; 2014 Jan; 89(1):43-51. PubMed ID: 24388021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
    Wang CC; Lu HT; Dusetzina SB; Wu CH
    J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate use after clinical fracture and risk of new fracture.
    Bergman J; Nordström A; Nordström P
    Osteoporos Int; 2018 Apr; 29(4):937-945. PubMed ID: 29397408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of acute myocardial infarction among new users of bisphosphonates: a nested case-control study.
    Mazzucchelli R; Rodríguez-Martín S; García-Vadillo A; Crespí-Villarías N; Gil M; Rodriguez-Miguel A; Barreira D; Garcia-Lledó A; de Abajo FJ
    Osteoporos Int; 2020 Dec; 31(12):2403-2412. PubMed ID: 32662036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for fracture among current, persistent users of bisphosphonates.
    LeBlanc ES; Rosales AG; Balasubramanian A; O'Malley CD; Egbuna O; Friess D; Perrin NA
    Osteoporos Int; 2015 Feb; 26(2):713-25. PubMed ID: 25354654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
    Bliuc D; Tran T; van Geel T; Adachi JD; Berger C; van den Bergh J; Eisman JA; Geusens P; Goltzman D; Hanley DA; Josse RG; Kaiser S; Kovacs CS; Langsetmo L; Prior JC; Nguyen TV; Center JR;
    Osteoporos Int; 2019 Apr; 30(4):817-828. PubMed ID: 30607457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate use and subsequent hip fracture in South Korea.
    Lee YK; Ha YC; Choi HJ; Jang S; Park C; Lim YT; Shin CS
    Osteoporos Int; 2013 Nov; 24(11):2887-92. PubMed ID: 23681088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment for older men with fractures.
    Shepherd AJ; Cass AR; Ray LA; Tan A; Wilkinson GS
    Osteoporos Int; 2012 Mar; 23(3):1041-51. PubMed ID: 21811867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
    Lin TC; Yang CY; Kao Yang YH; Lin SJ
    Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates.
    Ojeda-Bruno S; Naranjo A; Francisco-Hernández F; Erausquin C; Rúa-Figueroa I; Quevedo JC; Rodríguez-Lozano C
    Osteoporos Int; 2011 Jun; 22(6):1821-8. PubMed ID: 20924747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
    Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
    Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saving bones without risking brain-bisphosphonates and risk of stroke: matched case-control study.
    Asghar ZB; Godoy Caballero A; Pathirannehelage S; Williams J; McKay S; Grassby P; de Lusignan S; Niroshan Siriwardena A
    Osteoporos Int; 2019 Sep; 30(9):1845-1854. PubMed ID: 31214750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
    Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
    Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.